Bob will be talking to a host of studio guests, from back room staff to musicians who performed on the show and fans who grew up with it. Other former presenters including Annie Nightingale, Richard Williams, David Hepworth and Andy Kershaw will also feature, sharing stories of their time on the series. There will be incredible archive footage of some of the best loved and rarest performances from its extraordinary back catalogue, and during the live programme there will be an online viewer vote for the performance the BBC Four audience would most like to see again..
Going back to why fashion doesn design clothing with America largest demographic in mind they don want to. So everything we discussed is more than conceptual because there is no desire from brands to create plus sized clothing, even though the demand is there. It like people rarely dream of creating a brand that gets so big it becomes a household name because it sold at Walmart, always goes on sale, and is made of durable/practical clothing.
30, 2009. LaHood said enforcing restrictions on texting and cell phone use by drivers will be difficult. He urged the wireless industry to work with public officials to come up with a solution. I pretty much gone my whole life just seeing porn, liking the tie, then looking that up. Most of the techniques themselves are the same, but the execution does differ enough to learn them individually. This website goes over the basics..
I support their proposals,” said Rep. John Lewis(D Ga.). “They remind me of my generation of students and young people in the 1960s.”Notably, all fourDemocratic House leaders Leader Nancy Pelosi (D. None of this requires magicthat has never been performed before. We were adept at it for centuries. If we squinted just right, it was possible to look and see not a child but a commodity (“For SaleA Girl, Eleven years old, used to the care of children.
Could the same benefits be translated to those without established CVD (the majority of the patient population we see in clinical practice)? CANVAS PROGRAM was supposed to answer this vital question in addition to assessing CV outcomes in those with established CVD.What was the clinical impact of CANVAS PROGRAM?The only end points in which canagliflozin came out with flying colours were MACE hospitalisation due to heart failure.MACE benefits in only those with established CVD (mimicking EMPA REG trial).No reduction in all cause mortality.No reduction in CV deaths.Significant increase in rates of fractures lower limb amputations.To summarise treating patients with canagliflozin results in:23 fewer MACE (? clinical implication: in the absence of any superiority of the individual end points), 16 fewer hospitalisation due to heart failure, at the cost of 15 more amputations per 1000 patients treated for 5 years (1).Where does that leave us with?In a desperate bid to save the molecule there is an effort to generalise the amputation risk aspect.There is no escaping the fact that the amputation fracture related issue was haunting canagliflozin well before the CANVAS PROGRAM was published (indicated by the black box warnings).What was brought out in the forefront was an EMEA observation of imbalances in the amputation rates in females in the EMPA REG trial (4). Although the EMEA statements were contradictory, they wanted to scrutinise the entire empagliflozin dapagliflozin data before painting this entire class of molecules with the same brush.In July 19th 2017, the entire empagliflozin databank from phase 2 3 EMPA REG were analysed and there was no signal of either increased amputation nor fracture risk (5).Similarly the entire dapagliflozin polled phase 2 3 data did not indicate any adverse signals related to amputation fracture (6).So where do we stand as of now?Empagliflozin remains the gold standard therapy for all type 2 diabetes patients with established CVD with a very reassuring safety profile.Dapagliflozin has also documented its CV safety in polled phase 2 3 trials. Further clarifications will be available after publication oF DECLARE TIMI 58 results.Canagliflozin has MACE benefits but not any CV or all cause mortality benefits and at the cost of increased serious adverse effects.A recent news post from a reputed newspaper quoted a medical regulatory body and suggested that the physicians practicing as “Diabetologist” should be brought under the scanner.